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| INTRODUC TI ON
In a large subpopulation, clinically localized low-grade PC will remain indolent over the patient's lifetime 1, 2 ; consequently, the most important issues resulting from PC screening are overdiagnosis and overtreatment. 3, 4 Several randomized clinical trials have strongly suggested that intermediate-to high-risk cancers with GS of 7-10 benefit from aggressive therapy, such as radiotherapy or RP, by reducing mortality. [5] [6] [7] [8] Active surveillance is proposed for low-risk PC patients who meet the PRIAS criteria, 42%-80% of active surveillance patients experience a GS upgrade after RP [9] [10] [11] [12] ; therefore, the most efficient early detection strategy for PC would be to identify CSPC inexpensively before MRI to more effectively triage those men needing to proceed to Pbx.
Several assays provide prognostic information for HGPC (GS ≥ 7) at Pbx, such as the serum assays (Prostate Health Index and 4Kscore), [13] [14] [15] the DRE urine genetic tests (PCA3 and SelectMDx), 16 the tPSA plus urinary PCA3 tests (MiPS), 17 and first catch urine genetic test (EPI). 18 The reported AUC to evaluate the accuracy of predicting HGPC (GS ≥ 7) of these 6 assays ranged from 0.730 to 0.870, outperforming tPSA which has an AUC of 0.718. 13, 19, 20 We previously established an SPFS-based immunoassay system to detect PC-associated nonreducing terminal LacdiNAc (LDN, GalNAcβ1-4GlcNAc) structure carrying LDN-PSA in serum 21, 22 ( Figure   S1 ). A previous training cohort study on tPSA ≤ 20 ng/mL at initial Pbx (n = 442) reported that the diagnostic performance of LDN-PSA (AUC 0.795) outperformed that of tPSA (AUC 0.718). 20 In the present study, we retrospectively evaluated the diagnostic performance and clinical significance of LDN-PSA and LDN-PSAD in a Pbx multi-institutional cohort and in a single institutional preop-PSA cohort.
| MATERIAL S AND ME THODS

| Study design and assessments
A flow diagram of this observational study is shown in Figure 1 
| LacdiNAc-glycosylated PSA and LDN-PSAD tests
Serum LDN-PSA (mU/mL) was measured using SPFS-based immunoassay system as previously described. 20 LDN-PSAD (mU/mL/cm 3 ) was decision curve analysis showed that using a risk threshold of 20% and adding LDN-PSA calculated by dividing the LDN-PSA value by the prostate volume, as measured by transrectal ultrasonography. Serum tPSA and fPSA were measured using Architect i1000 (Abbott Japan, Tokyo, Japan). Laboratories) and nuclease-free water to a total reaction volume of 20 μL. The entire reaction mix was then loaded into a sample well of a DG8 cartridge for the QX200/QX100 droplet generator. Then 70 μL droplet generation oil was added for probes into the oil wells of the cartridge, according to the QX200/QX100 droplet generator instruction manual. After droplet generation, the droplets were transferred to a 96-well plate and sealed. Thermal cycling was carried out on the droplets using the Veriti Thermal Cycler (Thermo Fisher Scientific) according to the following protocol: enzyme activation at 95°C for 10 minutes, denaturation at 94°C for 30 seconds, followed by annealing/extension at 60°C for 1 minute (40 cycles), enzyme deactivation at 98°C for 10 minutes, followed by hold at 4°C. The ramp rate was set at 2°C/s, the heated lid to 105°C and the sample volume at 40 μL. After thermal cycling, the absolute gene expression level per well for the probes and reference genes were determined using a QX200/QX100 droplet reader and quantitated using QuantaSoft software (Bio-Rad Laboratories). For analysis of the gene expression data, we assumed a normal distribution. The gene expression values (absolute copy number) for each sample were normalized to the housekeeping gene ACTB. The PCR probes for human β4GALNT3 (unique assay ID: dHsaCPE5056467), human β4GALNT4 (unique assay ID: dHsaCPE5027332), and human β-actin (ACTB) (unique assay ID: dHsaCPE5190200) were purchased from the PrimePCR ddPCR Expression Probe Assay (Bio-Rad). Total protein from FFPE tissue was extracted by using the Formalin Fixed Paraffin Embedded Protein
| Quantification of
Isolation Kit (ITSI-Biosciences, Johnstown, PA, USA). To eliminate SDS, total protein solution was further treated by using SDS-eliminant reagent (ATTO, Tokyo, Japan). The LDN-PSA (mU/mL) of SDS-free protein solution from each tissue was measured using an SPFS-based immunoassay system as previously described. 20 Total PSA levels were measured using Architect i1000 (Abbott Japan, Tokyo, Japan).
| Statistical analyses
All statistical calculations were undertaken using GraphPad Prism 
| RE SULTS
The characteristics of the Pbx cohort (n = 718) and 384 patients belonging to the subgroup with 4-10 ng/mL tPSA are shown in Table 1 . The characteristics of the Pbx cohort belonging to the subgroup with 4-10 ng/mL tPSA (n = 384) are shown in Table 1 . Out of the 179 patients with PC, 26 patients, all with GS 6 were in the ASPC group.
Out of the 153 patients with CSPC, 9 (5.9%) had GS 6, 90 (58.8%) had GS 7, and 54 (35.3%) had GS ≥ 8. The age was significantly different in biopsy negative vs CSPC (P = 0.005), but not significantly different in biopsy negative vs ASPC (P = 0.155) and ASPC vs CSPC (P = 0.988). The DRE status, prostate volume, and levels of LDN-PSA and LDN-PSAD were significantly different in biopsy negative vs CSPC (all P < 0.0001) and ASPC vs CSPC (P = 0.009, P < 0.0001, P = 0.002, and P < 0.0001, respectively) but not significantly different in biopsy negative vs ASPC (P = 0.570, P = 0.186, P = 0.068, and P = 0.612, respectively). The tPSA level was significantly different in biopsy negative vs ASPC (P = 0.010) and ASPC vs CSPC (P = 0.001),
but not significantly different in biopsy negative vs CSPC (P = 0.074).
The F/T PSA level was significantly different in biopsy negative vs CSPC (P < 0.0001) and biopsy negative vs ASPC (P = 0.036), but not significantly different in ASPC vs CSPC (P = 0.954). The PSAD level was significantly different in biopsy negative vs ASPC (P = 0.008), biopsy negative vs CSPC (P < 0.0001) and ASPC vs CSPC (P < 0.0001).
In the Pbx cohort, LDN-PSAD levels in CSPC (median, 5.58 mU/ Figure 2A , Table 1 49.3%, respectively) were much higher than those of tPSA (21.6%, 27.0%, and 25.5%, respectively), and F/T PSA (25.9%, 28.3%, and 27.7%, respectively), and higher than those of PSAD (31.1%, 44.6%, and 46.8%, respectively) ( Table 2 ).
In the PSA gray zone cohort (subgroup of patients with 4-10 ng/ whereas tPSA and F/T PSA could not clearly discriminate ASPC from CSPC and/or biopsy negative ( Figure 2C , Table 1 Table 2 ). Furthermore, LDN-PSAD for discriminating HGPC also had TA B L E 1 Characteristics of 718 men who underwent a prostate biopsy and a subgroup of 384 men with 4-10 ng/mL total prostatespecific antigen (tPSA) At a preset 90% sensitivity, the specificities of LDN-PSAD to detect F I G U R E 2 Serum levels and receiver operating characteristic (ROC) curve analysis of LacdiNAc-glycosylated prostate-specific antigen (LDN-PSA), LDN-PSA normalized by prostate volume (LDN-PSAD), total (t)PSA, free PSA/tPSA (F/T PSA) ratio, and PSAD at prostate biopsy (Pbx) in patients diagnosed with prostate cancer (PC) or not. A, Violin plot of each test in overall Pbx cohort. Each PC group was classified as active surveillance-eligible Gleason sum 6 (ASGS6), non-AS-eligible GS6 (nonASGS6), GS7, GS8, GS9, and GS10. B, Violin plot of each test in gray zone PSA cohort (subgroup of patients with 4-10 ng/mL tPSA). PC group was classified as ASGS6, non-ASGS6, GS7, GS8, and GS9. Dashed red lines outline the interquartile range (IQR) of each test value. Solid red line represents the median of each test value. Multiple group differences were analyzed using the Kruskal-Wallis test for non-normally distributed models. C, Receiver operating characteristic (ROC) curves of overall PC, clinically significant (CS) PC (except for ASGS6 PC) and high grade (HG) PC (GS ≥ 7 PC) prediction accuracy of tPSA, fPSA/tPSA (F/T PSA), PSAD, LDN-PSA, and LDN-PSAD in the overall Pbx cohort. D, ROC curves of overall PC, CSPC, and HGPC prediction accuracy of tPSA, fPSA/tPSA (F/T PSA), PSAD, LDN-PSA, and LDN-PSAD in a cohort with PSA range 4-10 ng/mL Decision curve analyses predicting overall PC, CSPC, and HGPC in the Pbx cohort revealed that the base model (which included age,
F I G U R E 3 Comparison of decision curve analyses (DCA) of net benefit for a relevant risk threshold of a base model (age + digital rectal examination status + total prostate-specific antigen [tPSA] + free PSA/tPSA [F/T] PSA), base model + prostate volume, base model + PSA normalized by prostate volume (PSAD), base model + LacdiNAc-glycosylated PSA (LDN-PSA), base model + LDN-PSA + prostate volume, and base model + LacdiNAc-glycosylated PSAD (LDN-PSAD). A,G, DCA showing net benefit for carrying out biopsy in men at risk for overall prostate cancer (PC) in 718 men who underwent a prostate biopsy (Pbx cohort) (A) and in the gray zone PSA cohort (subgroup of patients with 4-10 ng/mL tPSA) (G). B,H, DCA showing net benefit for carrying out biopsy in men at risk for clinically significant PC (CSPC) in the Pbx cohort (B) and gray zone PSA cohort (H). C,I, DCA showing net benefit for carrying out biopsy in men at risk for high grade PC (HGPC) in the Pbx cohort (C) and gray zone PSA cohort (I). D,J, Avoidable biopsy rate per 100 patients without missing overall PC in the Pbx cohort (D) and gray zone PSA cohort (J). E,K, Avoidable biopsy rate per 100 patients without missing CSPC in the Pbx cohort (E) and gray zone PSA cohort (K). F,I Avoidable biopsy rate per 100 patients without missing CSPC in the Pbx cohort (F) and gray zone PSA cohort (I). DCA plots were developed using the rmda package of R statistical software
TA B L E 3 Net benefit and avoidable biopsies for the diagnostic model compared to the treat all strategy to biopsy every patient for different risk thresholds in a cohort of 718 men who underwent a prostate biopsy (Pbx) DRE status, tPSA, and F/T PSA) combined with LDN-PSAD had the largest net benefit for overall PC prediction at greater than 20% risk threshold, and for CSPC and HGPC prediction at greater than 15% risk threshold ( Figure 3A -C, Table 3 ). In the PSA gray zone cohort, the base model combined with LDN-PSAD also provided the largest net benefit for overall PC prediction at greater than 20% risk threshold, for CSPC and HGPC prediction at greater than 15% risk threshold ( Figure 3D -F and Table 3 (Table 3 ). These results
suggested that the base model combined with LDN-PSAD is the best option for detecting overall PC, CSPC, and HGPC at any PSA range.
To evaluate the significance of LDN-PSA or LDN-PSAD, we undertook multivariate logistic regression analyses (Table S1 ).
The odds ratio of LDN-PSAD for detection of overall PC (1.439; 95% CI, 1.251-1.655, P < 0.0001) and CSPC (1.492; 95% CI, University ( Figure 5A , Table 5 ). We found that the gene expression
Correlation between LacdiNAc-glycosylated prostate-specific antigen (LDN-PSA) levels and pathological parameters in preoperative baseline serum. A, Correlation between LDN-PSA levels and age, tumor volume, total (t)PSA levels, and free (f)PSA/tPSA (F/T PSA of β4GALNT4 and LDN-PSA/tPSA level was increased in Gleason pattern 4 and 5 tissues compared to benign ( Figure 5B ,C, Table 5 ). 26, 27 Consequently, the tPSA-based PC screening strategy has been changed and now includes the use of MRI to target HGPC and to avoid detection of low-grade cancer, retaining the potential to continue to reduce mortality but to avoid harm from overdetection of indolent PC.
| D ISCUSS I ON
We and others previously reported that LDN-PSA in serum is significantly increased in PC, 21, 28 especially HGPC with GS ≥ 7 20 and that the amount of LDN-glycan on PC tissue is positively correlated with higher GS and an independent risk factor of PSA recurrence. 20 Furthermore, we found that LDN-PSA/tPSA level and LDN-glycan synthesis-related β4GALNT4 gene expression was in- and transfection with β4GALNT4 reduced breast cancer cell growth in vitro. 29, 30 In contrast, the enhanced expression of LDN glycan has been shown to be associated with the progression of human prostate, ovarian, colon, and liver cancers. [31] [32] [33] 
TA B L E 5 (Continued)
and PSAD (AUC 0.809). We also found that including LDN-PSA or LDN-PSAD in a multivariate decision curve base model resulted in a significant increase in its accuracy for predicting overall PC, CSPC, and HGPC in patients without missing any cancer ( Figure 3 , Table 3 ).
Furthermore, we found that the LDN-PSA levels in the Pbx cohort 
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